Tubular aggregates and cylindrical spirals are two distinct ultrastructural abnormalities, observed on muscle biopsy, with similar histochemical staining characteristics on light microscopy. Both are found in a wide range of disorders. Recently a number of genetic mutations have been reported in conditions with tubular aggregates in skeletal muscle. It is widely accepted that TA arise from the sarcoplasmic reticulum, but the origin of cylindrical spirals has been less clearly defined. We describe the histopathological features of myopathies with tubular aggregates, including a detailed immunohistochemical analysis of congenital myasthenic syndromes with tubular aggregates due to mutations in GFPT1 and DPAGT1 and myopathies with cylindrical spirals. Our findings support the notion that cylindrical spirals, like tubular aggregates, derive primarily from the sarcoplasmic 3 reticulum, however, immunohistochemistry indicates that different molecular components of the sarcoplasmic reticulum may be involved and can be used to distinguish between these different inclusions. The immunohistochemical differences may also help to guide genetic testing.
INTRODUCTION
Tubular aggregates (TA) and cylindrical spirals (CS) are histopathological findings on muscle biopsy.
(1-3) They are of unknown aetiology and have been observed in patients with varied clinical disorders. Despite marked ultrastructural differences between TA and CS, they are indistinguishable with routine histochemical stains. It is widely accepted that TA arise from the sarcoplasmic reticulum (SR) but there have been few detailed studies of CS and their sub-cellular origin is unknown.
On ultrastructural examination, TA consist of tightly packed parallel arrays of single or double walled cylinders in the sarcoplasm. These typically stain bright red with modified Gömöri trichrome, strongly positive with nicotinamide adenine dinucleotide tetrazolium reductase (NADH-TR) and myoadenylate deaminase (MAD) and are negative with succinate dehydrogenase (SDH) and cytochrome c oxidase (COX). Evidence supporting the SR origin of TA comes from immunohistochemical (IHC) studies of genetically unclassified cases. (3-5) Nuclear, mitochondrial and sarcolemmal proteins have been described in TA, (6) (7) (8) suggesting that other organelles may play a role in their formation.
Although TA have been observed in inflammatory, metabolic and toxic myopathies, their presence defines a clinically heterogeneous group of disorders termed 'tubular aggregate myopathies' (TAM) which includes clinical phenotypes of exertional myalgia, limb girdle myopathy, periodic paralysis and congenital myasthenic syndromes (CMS). Recently, mutations in a number of genes have been described in some TAM. These include autosomal recessive (AR) mutations in GFPT1 and DPAGT1 which encode enzymes in the protein glycosylation pathway and cause CMS (9,10) and mutations in genes encoding proteins involved in calcium homeostasis, STIM1 and ORAI1 in TAM with miosis. (11, 12) Although the staining characteristics of TA are relatively uniform, differences have been reported. This variation could be accounted for by different genetic mutations.
Triggers resulting in the formation of TA are unknown. Their presence in a variety of clinical conditions may indicate that they are a non-specific response to metabolic derangements or toxic insults. It is suggested that they, like the SR, act as a calcium sink and are formed as a mitigating response to intracellular hypercalcaemia. (4) Others have proposed that they are a unique form of protein aggregation. (13) Cylindrical spirals (CS) are a rare finding on muscle biopsy. Ultrastructurally, they appear as groups of electron dense whorled cylinders in cross section. They have been reported in a number of unrelated conditions but are most frequently described in adults with myalgia and cramps. Despite their distinctive ultrastructural appearances, CS have similar staining characteristics to TA, appearing bright red with the modified Gömöri trichrome stain and negative with SDH. Like TA, the staining characteristics of CS are not invariable and they have been described as staining weakly, or brown rather than blue in colour with NADH-TR. (14) TA and CS have been observed within the same muscle biopsy, (14, 15) and in direct continuity at the ultrastructural level, (16) (17) (18) suggesting that they may have a common origin. However, detailed studies to validate these observations are lacking and the organelles from which CS are derived are undetermined. A recently published study of two Chinese siblings with myopathy and CS on muscle biopsy reported that CS may derive exclusively from the longitudinal SR (LSR). (19) We report a comprehensive study of the histochemical, IHC and ultrastructural features of these structural inclusions in myopathies with TA, including recently described CMS cases with mutations in GFPT1 and DPAGT1, non-CMS TAM cases, and myopathies with CS. 
MATERIALS AND METHODS

RESULTS
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The histopathological, IHC and EM findings are summarised in tables 2 and 3 and figures 1 and 2.
DPAGT1 and GFPT1 CMS with TA
Four CMS cases with DPAGT1 (n=2) and GFPT1 (n=2) mutations were analysed. At least two muscle biopsies were performed in all four cases. The mean time between biopsies was 11.2 years (range 5-16 years). Histopathological findings appeared to be more pronounced in later biopsies.
Vacuolated and necrotic fibres were increased in later biopsies in cases 2 and 3, while PAS staining was prominent in more recent biopsies in cases 2, 3 and 4. In cases 2 and 4 TA were universally small in the initial biopsies whereas in later biopsies small, medium and large TA were observed. However, the percentage of muscle fibres containing TA was no greater.
Myopathic changes, including variation in fibre size, increased numbers of internal nuclei, fibre atrophy and split fibres were present in all biopsies. Infrequent fibre necrosis and regeneration was observed in three of the four cases. There was an excess of COX negative fibres and ragged red fibres in case 2. Cytoplasmic bodies and eosinophilic nuclear inclusions were seen in cases 1 and 2 Ultrastructural analysis revealed DWTA in cases 5, 6 and 7 and a mixture of DWTA, SWTA and vesicular membrane collections in case 8. TA were accompanied by small groups of large neutral lipid droplet and, increased sarcoplasmic glycogen and thickening of the capillary basal lamina was observed.
Myopathies with CS
Biopsies revealed mild variation in fibre size in each of the two cases. Increased numbers of internal nuclei, fibre atrophy and two abnormal fibres, one containing rimmed vacuoles and a single ring fibre, were noted in case 9. There was a mild excess of COX negative fibres in case 10. Large basophilic subsarcolemmal aggregates were observed on H&E staining in both cases. These areas stained red with modified Gömöri trichrome and were positive with MAD staining but were unstained with SDH and COX. In case 9 aggregates were stained with PAS, but were unstained in case 10. On NADH-TR stained sections, aggregates appeared light blue in case 9 and dark blue in case 10. The morphology and distribution of aggregates differed between the two cases. In case 9 they were circular and appeared in type II fibres and in case 10 they were linear and present in type I and II fibres.
Aggregates were immunoreactive with antibodies to SERCA1 and SAR1. Ultrastructurally, subsarcolemmal clusters of CS were associated and interspersed with accumulated glycogen.
TA and CS in every case did not stain with antibodies for lamin A/C, COX IV, GM130, p62, myotilin, desmin, fast and slow myosins and Caveolin-3.
DISCUSSION
We describe the histopathological findings of inclusions in non-CMS TAM, CMS with TA associated with mutations in DPAGT1 and GFPT1 and myopathies with CS. Our results confirm that TA have characteristics suggesting they arise from the SR as reported in previous studies. We also describe the IHC characteristics of genetically confirmed cases of CMS with TA. TA and CS could not be clearly differentiated on routine tinctoral stains and enzyme histochemistry, and TA in non-CMS TAM and CMS cases could not be distinguished at the ultrastructural level. Our IHC findings support the hypothesis that CS, like TA, originate from the SR. IHC results were characteristic for each of the three groups we studied. The differences observed may permit the use of a panel of IHC to distinguish these three categories of inclusion without the need for ultrastructural examination.
We found that routine stains and histochemistry did not distinguish between TA in TAM and CS but there were differences between the TA observed in CMS cases and TAM. In the CMS cases, TA were unstained with H&E. In contrast, TA were strongly basophilic with H&E staining in non-CMS TAM Our findings support those of previous studies, confirming that TA arise from the SR and substantiate the hypothesis that CS originate from the SR. We did not find evidence to support the involvement of other organelles in the formation of TA or CS. Routine stains and histochemistry did not differentiate between CS and TA, however, the presence of TA in a muscle biopsy which are not apparent on H&E stained sections may, like rimmed vacuoles, be indicative of CMS. IHC results for TT, SR and ER exit site proteins were consistent and unique in each group of cases we studied. If this is confirmed in further studies, IHC could be used to distinguish between these three categories and may have a role to guiding genetic testing. The main limitation of our study is the small number of cases analysed, however, the rarity of TA and CS means that this is a major obstacle faced by all researchers in this area. A recent report of immunohistochemical studies in two siblings with CS, compared with two TAM cases, is in agreement with our findings, showing similar staining signatures for these different aggregates. (19) We conclude that these findings may indicate distinct mechanisms of formation for TA and CS, resulting in the incorporation of different elements of the SR.
